Researchers sought to compare the survival of patients with Duchenne muscular dystrophy treated with eteplirsen vs natural history control individuals.

In a network meta-analysis, researchers compared the effect of new treatments on health-related quality of life outcomes in patients with generalized myasthenia gravis with anti-acetylcholine receptor antibodies.

In a retrospective analysis, researchers characterized the prevalence and outcomes of neuropsychiatric conditions among patients hospitalized with and without neuromuscular diseases.

In an open-label extension study, researchers determined the long-term safety and efficacy of cipaglucosidase/miglustat in patients with Pompe disease.

Approval granted for once-daily, self-administered treatment in patients with anti-acetylcholine receptor-antibody-positive disease.

Researchers sought to assess whether the month or season of conception is associated with the risk of developing cerebral palsy.

In a systematic review and meta-analysis, researchers determined the clinical characteristics of patients with ocular MG and the proportion that would convert to secondary generalized MG.

The AEU is a patient- and physician-weighted consensus unit that quantifies and compares adverse event burden among different drugs, a study found.

Leflunomide  plus low-dose prednisone may improve the symptoms of myasthenia gravis in the long term, a study found.

Researchers presented the genetic, serologic, and clinical traits of patients with congenital myasthenic syndrome and juvenile myasthenia gravis.

In a cohort study, researchers assessed the relationship between SARS-CoV-2 infection and the development of Bell’s palsy.

Eculizumab has been approved in Japan for the treatment of children with generalized myasthenia gravis, a study found.

Patients with MG have significantly higher levels of neuroticism and significantly lower levels of openness and extraversion, a study found.

The phase 3 study evaluated pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy who are taking background corticosteroids.

Myasthenia gravis can be managed with intensive care unit resources, according to a 20-year retrospective study.

There may be a possible physiologic link between myasthenia gravis and depression, according to a new case study.

Researchers developed an artificial intelligence-based tool that can measure ptosis, or eyelid drooping, in patients with myasthenia gravis.

The Pfizer-BioNTech mRNA vaccine for COVID-19 does not appear to be associated with an increased risk for new-onset MG or MG exacerbations, a study found.

Risdiplam appears to be an effective therapeutic option for patients with spinal muscular atrophy, leading to improved motor function, a study found.

The FDA has granted Orphan Drug designation to AOC 1044 for the treatment of Duchenne muscular dystrophy with mutations amenable to exon 44 skipping.

Researchers assessed the use of neuromuscular electrical stimulation combined with early rehabilitation in improving muscle tone in patients on mechanical ventilation.

Researchers described the case of a patient, with achalasia and cricopharyngeal sphincter dysfunction who was later diagnosed with MG. 

Real-world data revealed long-term results regarding the efficacy and optimal safety profile of nusinersen for spinal muscular atrophy.

Researchers sought to determine the impact of deep neuromuscular block on patients who underwent spinal surgery.

Treatment with the SC formulation of efgartigimod alfa plus hyaluronidase-qvfc led to a lower risk of relapse in adults with CIDP.

The FDA has approved Rystiggo (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis in adults.

The FDA has approved Vyvgart Hytrulo for generalized myasthenia gravis in adult patients who are AChR antibody positive.

The FDA has approved Elevidys (delandistrogene moxeparvovec-rokl) for ambulatory pediatric patients 4 to 5 years of age with DMD.

Cerebral palsy pain can negatively affect an individual’s earnings and lower access to full-time employment.

For boys with cerebral palsy (CP), the presence of lower limb spasticity (LLS) is associated with orchidopexy risk.